One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis

BACKGROUND/AIMS: To evaluate the efficacy and safety of the PreserFlo MicroShunt glaucoma device in a multicentre cohort study. METHODS: All consecutive patients who received the microshunt with mitomycin-C (MMC) 0.4 mg/mL from May 2019 to September 2020 in three UK tertiary centres. Primary outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanner, Alexander, Haddad, Fadi, Fajardo-Sanchez, Julia, Nguyen, Ethan, Thong, Kai Xin, Ah-Moye, Sarah, Perl, Nicole, Abu-Bakra, Mohammed, Kulkarni, Avinash, Trikha, Sameer, Lascaratos, Gerassimos, Parnell, Miles, Kailani, Obeda, King, Anthony J, Agrawal, Pavi, Stead, Richard, Giannouladis, Konstantinos, Rodrigues, Ian, Goyal, Saurabh, Hysi, Pirro G, Lim, Sheng, Yu-Wai-Man, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359526/
https://www.ncbi.nlm.nih.gov/pubmed/35365491
http://dx.doi.org/10.1136/bjophthalmol-2021-320631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359526/
https://www.ncbi.nlm.nih.gov/pubmed/35365491
http://dx.doi.org/10.1136/bjophthalmol-2021-320631

Ejemplares similares